IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.478
AS - Asia 2.319
EU - Europa 2.258
SA - Sud America 220
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 6
Totale 8.317
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.424
CN - Cina 1.514
IE - Irlanda 498
UA - Ucraina 383
SG - Singapore 364
HK - Hong Kong 298
FI - Finlandia 295
DE - Germania 272
RU - Federazione Russa 232
BR - Brasile 182
IT - Italia 162
SE - Svezia 149
GB - Regno Unito 117
FR - Francia 46
CA - Canada 35
VN - Vietnam 34
IN - India 32
PL - Polonia 25
NL - Olanda 21
BE - Belgio 15
AR - Argentina 14
JP - Giappone 14
BD - Bangladesh 13
MX - Messico 12
ZA - Sudafrica 10
LT - Lituania 8
AT - Austria 7
ES - Italia 7
MU - Mauritius 7
TR - Turchia 7
AU - Australia 6
CO - Colombia 6
EU - Europa 6
PY - Paraguay 6
SA - Arabia Saudita 6
EC - Ecuador 5
VE - Venezuela 5
NP - Nepal 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
GR - Grecia 3
IL - Israele 3
IR - Iran 3
LA - Repubblica Popolare Democratica del Laos 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EG - Egitto 2
ID - Indonesia 2
IQ - Iraq 2
JM - Giamaica 2
JO - Giordania 2
MA - Marocco 2
NG - Nigeria 2
PA - Panama 2
PK - Pakistan 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HU - Ungheria 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MT - Malta 1
MY - Malesia 1
NO - Norvegia 1
PT - Portogallo 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UG - Uganda 1
Totale 8.317
Salva come PNG Salva come JPEG
Città #
Chandler 548
Dublin 498
Jacksonville 470
Nanjing 352
Hong Kong 298
Dallas 289
Beijing 228
Ashburn 202
Boardman 189
Nanchang 135
Singapore 131
Hebei 116
Princeton 112
Shenyang 109
Lawrence 108
Medford 102
Wilmington 102
Changsha 98
Los Angeles 91
New York 89
Ann Arbor 84
Jiaxing 69
Helsinki 63
Tianjin 61
Hangzhou 54
Munich 42
Shanghai 38
Woodbridge 38
Buffalo 35
Moscow 34
Redondo Beach 34
Milan 33
Warsaw 21
Turku 20
Council Bluffs 19
Santa Clara 18
Norwalk 16
San Francisco 16
Brussels 15
Ho Chi Minh City 15
Des Moines 14
Tokyo 14
Verona 14
Fairfield 13
Nuremberg 13
Pavia 13
Toronto 13
Falkenstein 12
Seattle 12
The Dalles 12
Auburn Hills 11
Brooklyn 9
Florence 9
Jinan 9
Johannesburg 9
Kunming 9
Rome 9
São Paulo 9
Boston 8
Ningbo 8
Pune 8
Genoa 7
Guangzhou 7
Montreal 7
Stockholm 7
Taizhou 7
Zhengzhou 7
Chennai 6
Chicago 6
Falls Church 6
Lanzhou 6
Poplar 6
Rio de Janeiro 6
Tappahannock 6
Xi'an 6
Atlanta 5
Columbus 5
Frankfurt am Main 5
Hanoi 5
London 5
Mexico City 5
New Delhi 5
Phoenix 5
Wuhan 5
Belo Horizonte 4
Charlotte 4
Dearborn 4
Manchester 4
Ribeirão Preto 4
Riyadh 4
Sumaré 4
Vienna 4
Washington 4
Augusta 3
Brasília 3
Calgary 3
Charleston 3
Chongqing 3
Ciudad del Este 3
Como 3
Totale 5.412
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 160
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 154
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 139
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 124
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 113
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 111
Blast phase of essential thrombocythemia: A single center study. 111
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 108
A gain-of-function mutation of JAK2 in myeloproliferative disorders 105
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 102
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 102
Clinical Predictors of Outcome in MPN. 101
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 101
Looking for CALR mutations in familial myeloproliferative neoplasms 100
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 99
JAK2 (V617F) mutation in healthy individuals 98
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 98
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 97
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 97
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 96
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 95
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 94
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 93
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 93
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 90
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 88
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 86
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 86
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 85
Leukemia risk models in primary myelofibrosis: an International Working Group study. 85
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 85
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 85
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 82
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 82
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 82
Clinical relevance of JAK2 (V617F) mutant allele burden 82
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 81
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 81
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 80
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 78
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 77
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 76
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 76
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 75
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 75
PDGFRB disease: right diagnosis to prolong survival 75
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 75
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 75
Leucemia mieloide cronica e sindromi mieloproliferative croniche 73
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 73
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 73
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 73
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 73
New generation small-molecule inhibitors in myeloproliferative neoplasms 73
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 73
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 73
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 72
Myeloproliferative Neoplasms 72
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 72
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 71
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 71
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 70
How I treat polycythemia vera. 70
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 68
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 68
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 68
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 67
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 67
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 67
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 67
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 67
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 66
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 66
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 66
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 65
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 65
Mutational status of myeloproliferative neoplasms. 64
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 64
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 63
How to manage polycythemia vera 63
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 63
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 63
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 63
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 62
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 62
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 62
Ruxolitinib and survival improvement in patients with myelofibrosis 60
What are RBC-transfusion-dependence and -independence? 60
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 60
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 60
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy 59
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. 59
RBC-transfusion guidelines update 58
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 58
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 58
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 54
JAK inhibitor in CALR-mutant myelofibrosis. 54
Leukemic transformation of polycythemia vera: a single center study of 23 patients 52
It is time to change thrombosis risk assessment for PV and ET? 51
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 50
Totale 7.904
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021441 0 0 0 0 7 90 5 100 28 96 94 21
2021/2022493 11 6 11 6 19 11 6 29 21 17 82 274
2022/20231.573 168 96 18 149 150 180 2 102 632 11 32 33
2023/2024537 79 92 16 48 34 157 3 33 4 11 15 45
2024/20251.427 29 127 36 39 40 66 43 117 335 34 229 332
2025/20261.443 280 335 413 347 68 0 0 0 0 0 0 0
Totale 8.430